AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02180776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Summit 456 TLSO
Description: Thoracolumbarsacral orthosis
Study NCT02888119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRISMA 3T MRI scanner (Siemens Medical Solutions)
Description: A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
Study NCT00031278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study NCT00031278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
Study NCT00031278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study NCT00031278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study NCT00031278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Study NCT00831480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
Study NCT00201188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Status Reports
Description: Interpreted Analysis of Peak-Flow Monitoring Trends
Study NCT03565497 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Education Control Condition
Description: As per arm of the same name
Study NCT03565497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: As per arm of the same name
Study NCT03565497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Plus IE
Description: As per arm of the same name
Study NCT01075685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive online programme to reduce alcohol consumption
Description: The programme includes several steps:~* personalized feedback on alcohol consumption and related risks~* reviewing motivations and fears regarding drinking reduction~* analyse of drinking habits~* reduction goal setting~* follow-up tools (alcohol diary, craving scales, well-being scales)~* a final screen allowing participants to monitor their progress through graphs and automatically adapted comments.
Study NCT01075685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimum information
Description: This intervention includes:~* information about hazardous drinking~* an alcohol diary
Study NCT01255683 — intervention group
Intervention type: DRUG
Intervention: oral corticosteroid taper
Description: This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
Study NCT01802996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate Injection
Description: 200mg IV on day 1-5
Study NCT01125696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/lamivudine/lopinavir-ritonavir
Description: Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
Study NCT01125696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine/lopinavir-ritonavir
Description: Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
Study NCT02592096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% Pazufloxacin Mesilate Ear Drops
Study NCT02592096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Pazufloxacin Mesilate Ear Drops
Study NCT02592096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Pazufloxacin Mesilate Ear Drops
Study NCT02592096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazufloxacin mesilate injection
Study NCT04565639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered Hand Orthosis
Description: A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
Study NCT03444636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine/Fentanyl
Description: Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
Study NCT03444636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/Fentanyl
Description: Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
Study NCT00380367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
Study NCT04301505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 1
Description: Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.
Study NCT04301505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 2
Description: The same checklist will be delivered at the beginning of the study and repeated after 6 months.
Study NCT02906176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole) intravenous infusion
Description: Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
Study NCT02906176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole) tablet
Description: Vfend (voriconazole) 200 mg tablet once
Study NCT02541396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine
Description: 35 or 70 mg ketamine in a sublingual wafer
Study NCT02541396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5 mg oxycodone capsule
Study NCT02541396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg oxycodone capsule
Study NCT02541396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule or placebo wafer
Study NCT02897856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal midazolam
Description: Study subject will receive Buccal midazolam, Intramuscular placebo.
Study NCT02897856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular midazolam
Description: Study subject will receive Intramuscular midazolam,Buccal placebo
Study NCT04223219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate >20% of baseline or hypertension: increase of blood pressure >20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study NCT04223219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl, Propofol
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study NCT04223219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, Ketamine, Magnesium sulfate
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study NCT01526759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LM pectin (10%)
Description: 15 days 1 daily consumption of a drink with 10g pectin added
Study NCT01526759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: gelatin
Description: 15 days 1 daily consumption of a drink with 10g gelatin added
Study NCT01092117 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ovation™ Abdominal Stent Graft System
Description: Implant of Ovation™ Abdominal Stent Graft System
Study NCT02138448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record
Description: The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
Study NCT04551534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL201
Description: Oral dose(s)
Study NCT04551534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose(s)
Study NCT03358524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 UNT
Description: Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
Study NCT03358524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: sugar capsule manufactured to mimic vitamin E capsule once per day
Study NCT01623050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSys Dilation System
Description: Sinuplasty
Study NCT02238080 — intervention group
Intervention type: DRUG
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
Study NCT06370403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling of the head and neck
Description: Cooling of the head and neck at 18°C next to the head and neck skin in multiple sclerosis and healthy subjects
Study NCT06370403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heating of the head and neck
Description: Heating of the head and neck at 43 ± 1°C next to the head and neck skin in multiple sclerosis
Study NCT01694407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir (TFV) Alone Vaginal Tablet
Description: vaginal tablet containing 40 mg of TFV
Study NCT01694407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine (FTC) Alone Vaginal Tablet
Description: Vaginal Tablet containing 40 mg of TFV
Study NCT01694407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TFV and FTC Combined Vaginal Tablet
Description: vaginal tablet with 40 mg TFV and 40 mg FTC
Study NCT01694407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Tablet
Description: Vaginal Tablet containing no drug
Study NCT00393861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Oxaliplatin
Description: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
Study NCT00332722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical facet joint nerve blocks
Study NCT00459186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Daily for two weeks
Study NCT00459186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Infusion once per cycle
Study NCT00459186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg by mouth twice daily
Study NCT02516852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg production
Description: Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
Study NCT02170415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protective analgesia
Description: Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day.
Study NCT02170415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain education
Description: Participant will receive a pain education leaflet
Study NCT02170415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological support
Description: Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
Study NCT02170415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block/local anaesthetic infiltration
Description: Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
Study NCT02170415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily visits from pain team whilst in hospital
Study NCT03415542 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Promotion
Description: Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
Study NCT02352155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine injection or heater probe or hemoclips
Description: Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
Study NCT02352155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation only
Description: Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
Study NCT02501395 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational
Study NCT00540332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
Study NCT00540332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: 120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
Study NCT04101942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
Study NCT00685568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
Study NCT00685568 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Orally, twice daily for 3 months
Study NCT02459834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose
Description: A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle.
Study NCT02459834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle.
Study NCT02459834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle.
Study NCT04462588 — intervention group
Intervention type: DRUG
Intervention: Cipro 400 MG in 200 ML Injection
Description: medical tratment group
Study NCT04462588 — intervention group
Intervention type: DRUG
Intervention: Flagyl I.V. RTU
Description: medical tratment group
Study NCT04462588 — intervention group
Intervention type: PROCEDURE
Intervention: appendectomy (open or laparascopic)
Description: appendectomy (open or laparascopic)
Study NCT01345357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
Study NCT01345357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Study NCT01345357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Study NCT02876536 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: The effect of TENS device will be compared in case and control groups.
Study NCT02876536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: The effect of TENS device will be compared in case and control groups.
Study NCT01209702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Administered intravenously (iv) every 4 weeks
Study NCT01209702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to tocilizumab administered intravenously every 4 weeks
Study NCT02121821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder messages
Description: The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).